Study: NCT04661579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine RTS,S/AS01E
Description: RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine RTS,S/AS01E
Description: RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine RTS,S/AS01E
Description: RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Abhayrab rabies vaccine
Description: Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Abhayrab rabies vaccine
Description: Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA/Pip)
Description: Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemether / Lumefantrine
Description: Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Primaquine
Description: One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.